Rethinking the metastatic cascade as a therapeutic target (Q37866635)

24 August 2017

1 reference

title

Rethinking the metastatic cascade as a therapeutic target (English)

1 reference

24 August 2017

Lida A Mina

1

1 reference

24 August 2017

George W Sledge

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

19 April 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

published in

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

325-332

1 reference

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Tumor angiogenesis: past, present and the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Metastasis suppressor genes: from gene identification to protein function and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Clinical targets for anti-metastasis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Tumor metastasis: mechanistic insights and clinical challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Metastasis: from dissemination to organ-specific colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Learning therapeutic lessons from metastasis suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

MicroRNAs and Metastasis: Little RNAs Go a Long Way

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

In vivo selection for metastasis promoting genes in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Molecular mechanisms of blood vessel growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Improving vaccine delivery using novel adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Cytotoxic T-lymphocyte-associated antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Dormancy of mammary carcinoma after mastectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Tumor cell dormancy: an NCI workshop report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Breast cancer dormancy can be maintained by small numbers of micrometastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Dormancy of solitary metastatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Does tumour dormancy offer a therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Targeted therapy: wave of the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Molecular MRI for sensitive and specific detection of lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

21 January 2018

Cancer micrometastases

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Pathology: are circulating tumor cells predictive of overall survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

A pooled analysis of bone marrow micrometastasis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Assessing the measure of a new drug: is survival the only thing that matters?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Liver-to-lung traffic of cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Matrix metalloproteinases: biologic activity and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Immunotherapy for advanced renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Comparison of breast cancer mortality rates with those of ovarian and colorectal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Annual hazard rates of recurrence for breast cancer after primary therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Circulating tumor cells in patients with breast cancer dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.59

Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis

31 March 2020

1 reference

12 December 2020

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

12 December 2020

Overcoming immune tolerance to cancer by heat shock protein vaccines

1 reference

12 December 2020

Molecular mechanisms of CD40 signaling.

1 reference

12 December 2020

Metastatic patterns in patients with carcinomas of the lower esophagus and upper rectum.

1 reference

12 December 2020

ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).

1 reference

12 December 2020

Role of platelet-derived growth factors in angiogenesis and alveogenesis

1 reference

12 December 2020

Receptor tyrosine kinase inhibitors as anti-angiogenic agents.

1 reference

12 December 2020

Challenges in the development of future treatments for breast cancer stem cells

1 reference

12 December 2020

Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64).

1 reference

12 December 2020

Differential expression of invasion promoting genes in childhood rhabdomyosarcoma

1 reference

12 December 2020

Cancer stem cells - A therapeutic target?

1 reference

12 December 2020

10.1038/NRCLINONC.2011.59

Identifiers

DOI

1 reference

24 August 2017

1 reference